Evidence map›Paper›PMID 38543845›Full record

ArticleViruses2024

Parvovirus B19 Outbreak in Israel: Retrospective Molecular Analysis from 2010 to 2023.

Orna Mor, Marina Wax, Shoshana-Shani Arami, Maya Yitzhaki, Or Kriger, Oran Erster, Neta S Zuckerman

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 26 citations in OpenAlex.

  1. Parvovirus: Conservative management of fetal anemia and hydrops.Acta obstetricia et gynecologica Scandinavica · 2025
    Review
  2. Article
  3. Article
  4. Is parvovirus B19 infection upsurge in 2023-2024 associated with adverse pregnancy outcome?Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology · 2025
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. An unusual outbreak of parvovirus B19 infections, France, 2023 to 2024.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Orna MorMedical School, Tel-Aviv University, Tel Aviv 6997801, Israel.ORCID 0000-0003-3207-4226
Marina WaxCentral Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Ramat Gan 5262112, Israel.
Shoshana-Shani AramiCentral Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Ramat Gan 5262112, Israel.ORCID 0009-0000-0185-9835
Maya YitzhakiCentral Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Ramat Gan 5262112, Israel.
Or KrigerClinical Microbiology and Pediatric Infectious Disease Unit, Chaim Sheba Medical Center, Ramat Gan 5262112, Israel.
Oran ErsterCentral Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Ramat Gan 5262112, Israel.
Neta S ZuckermanCentral Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Ramat Gan 5262112, Israel.
Sheba Medical Center · ILTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study presents an analysis of the epidemiological trends of parvovirus B19 (B19V) in Israel from 2010 to 2023, with particular emphasis on the outbreak in 2023. The analysis utilized molecular diagnostic data from individual patients obtained at the Central Virology Laboratory. Between 2010 and 2022, 8.5% of PCR-tested samples were positive for B19V, whereas in 2023, this percentage surged to 31% of PCR-tested samples. Throughout the study period, annual cycles consistently peaked in early spring/summer, with the most recent prominent outbreak occurring in 2016. Predominantly, diagnoses were made in children and women aged 20-39. Despite the notable surge in 2023, over 80% of positive cases continued to be observed in children and young women, with a decrease in cases during winter months. Furthermore, genotype 1a of the virus remained the predominant strain circulating during the outbreak. In light of these circumstances, consideration should be given to implementing screening measures, particularly among high-risk groups such as pregnant women.

Indexed as

Parvoviridae InfectionsParvovirus B19, HumanAntibodies, ViralChildDisease OutbreaksDNA, ViralFemaleHumansIsraelPregnancyRetrospective StudiesAntibodies, ViralDNA, ViralNGSoutbreakparvoB19RT-PCR

Identifiers

PMID38543845
PMCPMC10974090
OpenAlexW4392983874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.